<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716075</url>
  </required_header>
  <id_info>
    <org_study_id>PLRG12</org_study_id>
    <nct_id>NCT04716075</nct_id>
  </id_info>
  <brief_title>Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)</brief_title>
  <acronym>ACALLO</acronym>
  <official_title>Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic&#xD;
      hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC)&#xD;
      in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib&#xD;
      will be used before alloSCT with the intention to reduce tumor burden and after transplant to&#xD;
      augment disease control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic&#xD;
      hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC)&#xD;
      in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib&#xD;
      will be used before alloSCT with the intention to reduce tumor burden and after transplant to&#xD;
      augment disease control. Since chronic GvHD is mediated by activated B lymphocytes, we also&#xD;
      speculate that the drug as a BTK inhibitor may reduce the severity and incidence of chronic&#xD;
      graft-versus-host disease (GvHD) after alloSCT, as it was shown for ibrutinib.&#xD;
&#xD;
      Best response to therapy and safety issues will be the primary target of this small trial (25&#xD;
      transplanted pts).TEAE and SAE of acalabrutinib in patients after alloSCT that was not&#xD;
      previously assessed.&#xD;
&#xD;
      We hypothesize that this treatment will improve the efficacy of the alloSCT - this issue will&#xD;
      be addressed by serial minimal residual disease (MRD) evaluation in peripheral blood and bone&#xD;
      marrow. This treatment strategy could significantly improve the outcome of poor prognosis MCL&#xD;
      and CLL patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicentre, national</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to therapy - Response Rate</measure>
    <time_frame>through study completion on average 27 months</time_frame>
    <description>- partial and complete remission rate (PR and CR),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to therapy Minimum residual disease CR (MRD CR) rate</measure>
    <time_frame>through study completion on average 27 months</time_frame>
    <description>minimum residual disease CR (MRD CR) assessed by flow cytometry in peripheral blood (PB) and bone marrow (BM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse event/serious adverse event incidence</measure>
    <time_frame>acalabrutinib completion or discontinuation plus 30 days of the last acalabrutinib dose</time_frame>
    <description>Incidence of adverse events per system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>through study completion on average 27 months</time_frame>
    <description>defined as death in continuous remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>through study completion on average 27 months</time_frame>
    <description>return of a disease or the signs and symptoms of a disease after a period of improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>through study completion on average 27 months</time_frame>
    <description>defined as the time from assignment in a clinical trial to disease progression or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Graft-versus-host-disease</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Adverse Event</condition>
  <condition>Response Rate</condition>
  <arm_group>
    <arm_group_label>Acalabrutinib 2x100mg oral capsule +alloSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib 2x100 MG Oral Capsule + alloSCT</intervention_name>
    <description>Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Acalabrutinib 2x100mg oral capsule +alloSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 18 years of age.&#xD;
&#xD;
          2. Relapsing / refractory BTK-inhibitors naïve CLL patients meeting IWCCL criteria for&#xD;
             requiring treatment:&#xD;
&#xD;
               1. after 1-4 therapy lines if del 17 or p53 mutation in &gt;10% of analyzed CLL cells&#xD;
                  (PB or BM) or&#xD;
&#xD;
               2. after 2-4 therapy lines if high risk CLL (refractory or less than 24 months&#xD;
                  response to the last immunochemotherapy) or Confidential Page 15 of 82 Study&#xD;
                  Protocol v. 1.5 dated 06.07.2018&#xD;
&#xD;
          3. Relapsing / refractory BTK-inhibitors naïve MCL patients with measurable disease or&#xD;
             bone marrow involvement revealed in trephine biopsy or&#xD;
&#xD;
          4. Patients fulfilling criteria 2 or 3, when ibrutinib therapy was initiated, responding&#xD;
             to therapy&#xD;
&#xD;
          5. Patient qualified for allo SCT procedure by the transplant center participating in the&#xD;
             trial with identified sibling donor or initiated Poltransplant search for matched&#xD;
             unrelated donor.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Woman of childbearing potential (WOCBP) who are sexually active must use highly&#xD;
             effective methods of contraception during treatment and for 2 days after the last dose&#xD;
             of acalabrutinib and for 6 months after the transplant procedure if performed. Males&#xD;
             who are sexually active must use highly effective methods of contraception during&#xD;
             treatment and for 6 months after the transplant procedure if performed.&#xD;
&#xD;
          8. Willing and able to participate in all required evaluations and procedures in this&#xD;
             study protocol including swallowing capsules without difficulty.&#xD;
&#xD;
          9. Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients failing 5 or more previous therapy lines&#xD;
&#xD;
          2. Prior malignancy (or any other malignancy that requires active treatment), except for&#xD;
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,&#xD;
             or other cancer from which the subject has been disease free for ≥ 5 years&#xD;
&#xD;
          3. Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or Confidential Page 16 of 82 Study Protocol v. 1.5 dated 06.07.2018 any&#xD;
             Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional&#xD;
             Classification (NYHA). Subjects with controlled, asymptomatic atrial fibrillation&#xD;
             during screening can enroll on study.&#xD;
&#xD;
          4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel that is likely to affect absorption,&#xD;
             symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or&#xD;
             gastric restrictions and bariatric surgery, such as gastric bypass.&#xD;
&#xD;
          5. Impaired hepatic function (as indicated by any of the following):&#xD;
&#xD;
               1. Serum total bilirubin &gt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
               2. Alanine amino transferase and/or aspartate amino transferase &gt; 2.5 x ULN&#xD;
&#xD;
               3. Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          6. Impaired renal function: serum creatinine &gt; 2.5 x ULN&#xD;
&#xD;
          7. Other concurrent serious diseases that increase Hematopoietic Cell&#xD;
             Transplantation-Comorbidity Index (HCT-CI) &gt; 4&#xD;
&#xD;
          8. Central nervous system involvement with CLL&#xD;
&#xD;
          9. Known history of drug-specific hypersensitivity or anaphylaxis to study drug&#xD;
             (including active product or excipient components).&#xD;
&#xD;
         10. Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand&#xD;
             disease).&#xD;
&#xD;
         11. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic&#xD;
             purpura).&#xD;
&#xD;
         12. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before&#xD;
             screening.&#xD;
&#xD;
         13. Requiring or receiving a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer (see&#xD;
             appendix 3 for a complete list) Confidential Page 17 of 82 Study Protocol v. 1.5 dated&#xD;
             06.07.2018&#xD;
&#xD;
         14. Requiring or receiving anticoagulation with warfarin or equivalent vitamin K&#xD;
             antagonists (eg, phenprocoumon) within 7 days of first dose of study drug.&#xD;
&#xD;
         15. Requiring proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole,&#xD;
             dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump&#xD;
             inhibitors who switch to H2-receptor antagonists or antacids are eligible for&#xD;
             enrollment to this study.&#xD;
&#xD;
         16. Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) &gt; 2x ULN.&#xD;
&#xD;
         17. History of significant cerebrovascular disease or event, including stroke or&#xD;
             intracranial hemorrhage, within 6 months before the first dose of study drug.&#xD;
&#xD;
         18. Major surgical procedure within 30 days of first dose of study drug. Note: If a&#xD;
             subject had major surgery, they must have recovered adequately from any toxicity&#xD;
             and/or complications from the intervention before the first dose of study drug.&#xD;
&#xD;
         19. Known history of infection with HIV or any active uncontrolled systemic infection&#xD;
&#xD;
         20. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody&#xD;
             (anti-HBc) positive and who are surface antigen negative will need to have a negative&#xD;
             polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg)&#xD;
             positive or hepatitis B PCR positive will be excluded.&#xD;
&#xD;
             Subjects who are hepatitis C antibody positive will need to have a negative PCR&#xD;
             result. Those who are hepatitis C PCR positive will be excluded.&#xD;
&#xD;
         21. ANC &lt; 500/μl, Platelets &lt; 20 000/μl, and hemoglobin &lt; 8 g/dl&#xD;
&#xD;
         22. Breastfeeding or pregnant.&#xD;
&#xD;
         23. Concurrent participation in another therapeutic clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Giebel, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Polish Lymphoma Research Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Jurczak, Prof.</last_name>
    <phone>+48126348268</phone>
    <email>wojciech.jurczak@lymphoma.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Czyż, Prof.</last_name>
    <phone>+ 48 71 7842576</phone>
    <email>aczyz@onet.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Intytut Onkologii im. M. Skłodowskiej-Curie Oddział w Krakowie, Pododdział Leczenia Nowotworów Układu Chłonnego</name>
      <address>
        <city>Kraków</city>
        <state>Małopolska</state>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wojciech Jurczak, MD PhD Prof.</last_name>
      <phone>+48 602 338290</phone>
      <email>Wojciech Jurczak &lt;wojciech.jurczak@lymphoma.edu.pl&gt;</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku i Onkohematologii; Centrum Onkologii Instytut im. M.Sklodowskiej-Curie, Oddz. w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Najda, MD PhD</last_name>
      <phone>+48 501315101</phone>
      <email>jacek.najda@io.gliwice.pl</email>
    </contact>
    <contact_backup>
      <last_name>Malgorzata Sobczyk-Kruszelnicka, MD</last_name>
      <phone>+48600048575</phone>
      <email>Małgorzata Sobczyk-Kruszelnicka &lt;Malgorzata.Kruszelnicka@io.gliwice.pl&gt;</email>
    </contact_backup>
    <investigator>
      <last_name>Sebastian Giebel Giebel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacek Najda, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malgorzata Sobczyk-Kruszelnicka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego, Oddział Hematologii i Transplantacji Szpiku</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidia Gil, MD PhD Prof.</last_name>
      <phone>+48 601 583 587</phone>
      <email>lidia.gil@skpp.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii - im. Marii Skłodowskiej- Curie -Państwowy Instytut Badawczy Klinika Nowotworów Układu Chłonnego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanna Romejko-Jarosińska, MD PhD</last_name>
      <phone>+48 22-546-2448</phone>
      <email>Joanna.Romejko-Jarosinska@pib-nio.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytetu Medycznego</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Czyż, MD, PhD, Prof</last_name>
      <phone>+48 601 753 371</phone>
      <email>a.czyz &lt;a.czyz@umed.wroc.pl&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Agnieszka Szeremet, MD PhD</last_name>
      <email>Agnieszka Szeremet &lt;agnieszka.szeremet@wp.pl&gt;</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acalabrutinib</keyword>
  <keyword>Chronic Lymphocytic Leukaemia</keyword>
  <keyword>allogeneic haematopetic cell transplantation</keyword>
  <keyword>Chronic Graft-versus-host-disease</keyword>
  <keyword>Minimal Residual Disease</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>Mantle Cell Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acalabrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04716075/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

